PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 1

Complete if Known				
Application Number	09/744,875			
Filing Date	January 29, 2001			
First Named Inventor	- Kenneth S. Zuckerman			
Group Art Unit	1635			
Examiner Name	Mary M. Schmidt			
Attorney Docket Number	USF-T176X			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
2	R1	DUSANTER-FOURT et al. "Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin- erythropoietin receptor chimera expressed in lymphoid cells," The EMBO Journal, 1994, Vol. 13, No. 11, pp. 2583-2591.			
W	R2	GEWIRTZ et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects," Blood, 1998, Vol. 92, No. 3, pp. 712-736.			
7	R3	GORODETSKY et al. "Isolation and characterization of the Bos Taurus β-casein gene," Gene, 1988, Vol. 66, pp. 87-96.			
2	R4	GREENBERG et al. "Characterization of a New Megakaryocytic Cell Line: The Dami Cell," Blood, 1988, Vol. 72, No. 6, pp. 1968-1977.			
W	R5	HONG et al. "Inhibition of Protein Kinase C Suppresses Megakaryocytic Differentiation and Stimulates Erythroid Differentiation in HEL Cells," <i>Blood</i> , 1996, Vol. 87, No. 1, pp. 123-131.			
K	R6	MARTIN "HEL Cells: A New Human Erythroleukemia Cell Line with Spontaneous and Induced Globin Expression," Science, 1982, Vol. 216, pp. 1233-1235.			
M	R7	OGURA et al. "Establishment of a Novel Human Megakaryoblastic Leukemia Cell Line, MEG-01, With Positive Philadelphia Chromosome," <i>Blood</i> , 1985, Vol. 66, No. 6, pp. 1384-1392.			
~	R8	IYER et al. "The Automated Synthesis of Sufur-Containing Oligodeoxyribonucleotides Using 3H-1,2-Benzodithiol-3-one 1,1-Dioxide as a Sulfur-Transfer Reagent," J. Org. Chem., 1990, Vol. 55, pp. 4693-4699.			
2	R9	WOOLF et al. "The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos," <i>Nucleic Acids Research</i> , 1990, Vol. 18, No. 7, pp. 1763-1769.			
W	R10	YU et al. "Attenuation of Serum Inducibility of Immediate Early Genes by Oncoproteins in Tyrosine Kinase Signaling Pathways," Molecular and Cellular Biology, 1993, Vol. 13, No. 4, pp. 2011-2019.			
M	R11	Appleton & Lange, Critical Care Diagnosis & Treatment, Edited by Frederic S. Bongard and Darryl Y. Sue, Paramount Publishing Business and Professional Group.			
8	R12	PCR Protocols: A Guide to Methods and Applications, Edited by Michael A. Innis et al., Academic Press, Inc., 1990.			

Examiner	The state of the s	Date	_/	f
Signature		Considered /	141 ₁	14
			-	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, ineltide copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

4

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.